Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

american health packaging - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250 tm neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250tm neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

carilion materials management - sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, anhydrous 852 mg - phospha 250 neutral increases urinary phosphate and pyrophosphate. as a phosphorus supplement, each tablet supplies 25% of the u.s. recommended daily allowance (u.s. rda) of phosphorus for adults and children over 4 years of age. tm this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia. . see dosage and administration

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in the following conditions: -   history of acute phosphate nephropathy [see warnings and precautions (5.1)] -   gastrointestinal (gi) obstruction [see warnings and precautions (5.7)] -   gastric bypass or stapling surgery -   bowel perforation -   toxic colitis -   toxic megacolon -   hypersensitivity to sodium phosphate salts or any component of monobasic sodium phosphate and dibasic sodium phosphate tablets[see warnings and precautions (5.7)]. risk summary there are no available data on sodium phosphate use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with sodium phosphate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of sodium phosphate in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of monobasic sodium phosphate and dibasic sodium phosphate tablets to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for monobasic sodium phosphate and dibasic sodium phosphate tablets and any potential adverse effects on the breastfed child from monobasic sodium phosphate and dibasic sodium phosphate tablets or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. of the 599 patients in clinical trials receiving at least 48 grams of monobasic sodium phosphate and dibasic sodium phosphate tablets, 134 (22%) were 65 years of age or older, while 27 (5%) were 75 years of age or older. no overall differences in safety or effectiveness were observed between geriatric patients and younger patients. however, the mean phosphate levels in geriatric patients were greater than the phosphate levels in younger patients after monobasic sodium phosphate and dibasic sodium phosphate tablets administration. the mean colonoscopy-day phosphate levels in patients 18-64, 65-74, and ≥ 75 years old who received the recommended monobasic sodium phosphate and dibasic sodium phosphate tablets dosage regimen in study 1were 7.0, 7.3, and 8.0 mg/dl, respectively. after monobasic sodium phosphate and dibasic sodium phosphate tablets administration, the mean phosphate levels in patients 18-64, 65-74, and ≥ 75 years old were 7.4, 7.9, and 8.0 mg/dl, respectively. greater sensitivity of some older individuals cannot be ruled out; therefore, use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in geriatric patients. advise geriatric patients to adequately hydrate before, during, and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets. sodium phosphate is known to be substantially excreted by the kidney, and the risk of adverse reactions with sodium phosphate may be greater in patients with impaired renal function. since geriatric patients are more likely to have impaired renal function, consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1)]. sodium phosphate is substantially excreted by the kidney. use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in patients with severe renal impairment (creatinine clearance less than 30 ml/min) or patients taking concomitant medications that may affect renal function. these patients may be at risk for renal injury. advise these patients of the importance of adequate hydration before, during and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets, and consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1), drug interactions (7.1)] .

Kanada - inglise - Health Canada

biocentre - potassium phosphate dibasic - tablet - 6x - potassium phosphate dibasic 6x - homeopathic products

Kanada - inglise - Health Canada

sandoz canada incorporated - potassium phosphate monobasic; potassium phosphate dibasic - liquid - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations

Kanada - inglise - Health Canada

lyphomed, division of fujisawa canada inc. - potassium phosphate monobasic; potassium phosphate dibasic - liquid - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations

Kanada - inglise - Health Canada

total health centre - potassium phosphate dibasic - liquid - 1x - potassium phosphate dibasic 1x - homeopathic products

Kanada - inglise - Health Canada

hospira healthcare ulc - potassium phosphate monobasic; potassium phosphate dibasic - solution - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

american regent, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)] - hyperphosphatemia [see warning and precautions (5.4)] - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] - severe renal impairment (egfr less than 30 ml/min/1.73m2 ) or end stage renal disease [see warning and precautions (5.3)] risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates inj